Abiopharma

NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

New Form SCHEDULE 13G/A - Praxis Precision Medicines, Inc. Filed: 2025-05-15 AccNo: 0001172661-25-002195 Size: 10 KB

New Form SCHEDULE 13G - AETHLON MEDICAL INC Filed: 2025-05-15 AccNo: 0001172661-25-002193 Size: 10 KB

New Form 10-Q - UTAH MEDICAL PRODUCTS INC Filed: 2025-05-15 AccNo: 0001096906-25-000816 Size: 2 MB

New Form SCHEDULE 13G - CARGO Therapeutics, Inc. Filed: 2025-05-15 AccNo: 0001172661-25-002194 Size: 10 KB

Philips successfully prices offering of Notes for EUR 1 billion to be used for repayment of existing debt and to finance eligible green projects

New Form 10-Q - Spectral AI, Inc. Filed: 2025-05-15 AccNo: 0001213900-25-044076 Size: 4 MB

New Form 10-Q - Elite Health Systems Inc. Filed: 2025-05-15 AccNo: 0001437749-25-017141 Size: 3 MB

New Form 3 - Cyclacel Pharmaceuticals, Inc. Filed: 2025-05-15 AccNo: 0001641172-25-010741 Size: 3 KB

New Form SCHEDULE 13G/A - ORTHOPEDIATRICS CORP Filed: 2025-05-15 AccNo: 0001398344-25-009614 Size: 7 KB

New Form 3 - Cyclacel Pharmaceuticals, Inc. Filed: 2025-05-15 AccNo: 0001641172-25-010738 Size: 3 KB

New Form 10-Q - America Great Health Filed: 2025-05-15 AccNo: 0001185185-25-000484 Size: 5 MB

Jaguar Health Reports First Quarter 2025 Financials

New Form SCHEDULE 13G - Evolent Health, Inc. Filed: 2025-05-15 AccNo: 0001011438-25-000315 Size: 16 KB

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States